Compare $DYAI vs $NEUP | Chartloom

Compare

$DYAI vs $NEUP

Dyadic International Inc · Neuphoria Therapeutics Inc

DYAI

Dyadic International Inc

NEUP

Neuphoria Therapeutics Inc

Compare $DYAI vs $NEUP

Comparing Dyadic International Inc and Neuphoria Therapeutics Inc

DYAIDyadic International Inc

NEUPNeuphoria Therapeutics Inc

DYAIDyadic International Inc

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.15x

Rev growth (TTM)

-8.1%

YTD performance

-52.8%

52W performance

-60.7%

FCF yield

-45.8%

NEUPNeuphoria Therapeutics Inc

Market cap

$18M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-92.5%

YTD performance

-12.0%

52W performance

-81.7%

FCF yield

-68.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DYAI

NEUP

Detailed metrics comparison

DYAI

Dyadic International Inc

NEUP

Neuphoria Therapeutics Inc

Market Cap

DYAI$16M

NEUP$18M

Enterprise Value

DYAI$20M

NEUP$-2M

Price

DYAI$0.44

NEUP$3.36

P/E Ratio

DYAIN/A

NEUPN/A

P/S Ratio

DYAI4.26x

NEUP15.45x

EV/Sales

DYAI5.21x

NEUP-1.44x

EV/EBITDA

DYAI75.44x

NEUP0.00x

P/B Ratio

DYAI14.82x

NEUP0.76x

P/FCF Ratio

DYAIN/A

NEUPN/A

EV/FCF

DYAI-2.67x

NEUP0.14x

PEG Ratio

DYAIN/A

NEUPN/A

Forward P/E (NTM)

DYAIN/A

NEUPN/A

Forward P/S (NTM)

DYAI2.15x

NEUPN/A

Revenue (TTM)

DYAI$4M

NEUP$1M

Revenue Growth (YoY)

DYAI-8.1%

NEUP-92.5%

Forward Rev Growth

DYAI91.1%

NEUP0.0%

Gross Margin (TTM)

DYAI16.2%

NEUP0.0%

Operating Margin (TTM)

DYAI0.0%

NEUP0.0%

EBITDA Margin (TTM)

DYAI-194.5%

NEUP-779.0%

Net Margin (TTM)

DYAI-200.5%

NEUP-1145.6%

FCF Margin (TTM)

DYAI-194.7%

NEUP-1052.0%

Net Income (TTM)

DYAI$-8M

NEUP$-13M

FCF (TTM)

DYAI$-7M

NEUP$-12M

EPS (TTM)

DYAI-$0.21

NEUP-$2.49

ROE (TTM)

DYAI-35086.0%

NEUP-5591.0%

ROA (TTM)

DYAI-8477.0%

NEUP-4222.0%

ROIC (TTM)

DYAI-8444.0%

NEUP-5583.0%

Cash

DYAI$1M

NEUP$20M

Debt

DYAI$5M

NEUP$34K

Net Cash/Debt

DYAI$-4M

NEUP$20M

Current Ratio (TTM)

DYAI1.65x

NEUP27.85x

Quick Ratio (TTM)

DYAI1.54x

NEUP27.33x

Debt/Equity (TTM)

DYAI4.08x

NEUP0.00x

Debt/Assets (TTM)

DYAI0.0%

NEUP0.0%

Interest Coverage (TTM)

DYAIN/A

NEUPN/A

Net Debt/EBITDA (TTM)

DYAI0.00x

NEUP0.00x

Beta

DYAI1.09

NEUP0.76

52W Performance

DYAI-60.7%

NEUP-81.7%

YTD Performance

DYAI-52.8%

NEUP-12.0%

% from 52W High

DYAI-72.2%

NEUP-82.5%

% from 52W Low

DYAI30.6%

NEUP5.3%

Asset Turnover (TTM)

DYAI0.42x

NEUP0.04x

FCF Yield (TTM)

DYAI-45.8%

NEUP-68.1%

Earnings Yield (TTM)

DYAI-47.1%

NEUP-74.1%

Dividend Yield (TTM)

DYAIN/A

NEUPN/A

Rule of 40

DYAI-202.8

NEUP-1,144.5

EV/GP/RG

DYAI0.30

NEUPN/A

Ticker research

View DYAI research View NEUP research

Metric	DYAI Dyadic International Inc	NEUP Neuphoria Therapeutics Inc
Market & Valuation
Market Cap	$16M	$18M
Enterprise Value	$20M	$-2M
Price	$0.44	$3.36
P/E Ratio	N/A	N/A
P/S Ratio	4.26x	15.45x
EV/Sales	5.21x	-1.44x
EV/EBITDA	75.44x	0.00x
P/B Ratio	14.82x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.67x	0.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.15x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$1M
Revenue Growth (YoY)	-8.1%	-92.5%
Forward Rev Growth	91.1%	0.0%
Profitability
Gross Margin (TTM)	16.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-194.5%	-779.0%
Net Margin (TTM)	-200.5%	-1145.6%
FCF Margin (TTM)	-194.7%	-1052.0%
Net Income (TTM)	$-8M	$-13M
FCF (TTM)	$-7M	$-12M
EPS (TTM)	-$0.21	-$2.49
ROE (TTM)	-35086.0%	-5591.0%
ROA (TTM)	-8477.0%	-4222.0%
ROIC (TTM)	-8444.0%	-5583.0%
Financial Health
Cash	$1M	$20M
Debt	$5M	$34K
Net Cash/Debt	$-4M	$20M
Current Ratio (TTM)	1.65x	27.85x
Quick Ratio (TTM)	1.54x	27.33x
Debt/Equity (TTM)	4.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.09	0.76
52W Performance	-60.7%	-81.7%
YTD Performance	-52.8%	-12.0%
% from 52W High	-72.2%	-82.5%
% from 52W Low	30.6%	5.3%
Efficiency & Yields
Asset Turnover (TTM)	0.42x	0.04x
FCF Yield (TTM)	-45.8%	-68.1%
Earnings Yield (TTM)	-47.1%	-74.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-202.8	-1,144.5
EV/GP/RG	0.30	N/A
Ticker research	View DYAI research	View NEUP research

Valuation

P/S Ratio

DYAI

4.26x

NEUP

15.45x

EV/FCF

DYAI

-2.67x

NEUP

0.14x

Growth & revenue

Revenue Growth TTM

DYAI

-8.1%

NEUP

-92.5%

Forward Revenue Growth

DYAI

91.1%

NEUP

0.0%

Profitability & performance

Gross Margin

DYAI

16.2%

NEUP

0.0%

ROE

NEUP

-5591.0%

DYAI

-35086.0%

FCF Yield %

DYAI

-45.8%

NEUP

-68.1%

52-Week Performance

DYAI

-60.7%

NEUP

-81.7%

Detailed metrics comparison

DYAI

Dyadic International Inc

NEUP

Neuphoria Therapeutics Inc

Market Cap

DYAI$16M

NEUP$18M

Enterprise Value

DYAI$20M

NEUP$-2M

Price

DYAI$0.44

NEUP$3.36

P/E Ratio

DYAIN/A

NEUPN/A

P/S Ratio

DYAI4.26x

NEUP15.45x

EV/Sales

DYAI5.21x

NEUP-1.44x

EV/EBITDA

DYAI75.44x

NEUP0.00x

P/B Ratio

DYAI14.82x

NEUP0.76x

P/FCF Ratio

DYAIN/A

NEUPN/A

EV/FCF

DYAI-2.67x

NEUP0.14x

PEG Ratio

DYAIN/A

NEUPN/A

Forward P/E (NTM)

DYAIN/A

NEUPN/A

Forward P/S (NTM)

DYAI2.15x

NEUPN/A

Revenue (TTM)

DYAI$4M

NEUP$1M

Revenue Growth (YoY)

DYAI-8.1%

NEUP-92.5%

Forward Rev Growth

DYAI91.1%

NEUP0.0%

Gross Margin (TTM)

DYAI16.2%

NEUP0.0%

Operating Margin (TTM)

DYAI0.0%

NEUP0.0%

EBITDA Margin (TTM)

DYAI-194.5%

NEUP-779.0%

Net Margin (TTM)

DYAI-200.5%

NEUP-1145.6%

FCF Margin (TTM)

DYAI-194.7%

NEUP-1052.0%

Net Income (TTM)

DYAI$-8M

NEUP$-13M

FCF (TTM)

DYAI$-7M

NEUP$-12M

EPS (TTM)

DYAI-$0.21

NEUP-$2.49

ROE (TTM)

DYAI-35086.0%

NEUP-5591.0%

ROA (TTM)

DYAI-8477.0%

NEUP-4222.0%

ROIC (TTM)

DYAI-8444.0%

NEUP-5583.0%

Cash

DYAI$1M

NEUP$20M

Debt

DYAI$5M

NEUP$34K

Net Cash/Debt

DYAI$-4M

NEUP$20M

Current Ratio (TTM)

DYAI1.65x

NEUP27.85x

Quick Ratio (TTM)

DYAI1.54x

NEUP27.33x

Debt/Equity (TTM)

DYAI4.08x

NEUP0.00x

Debt/Assets (TTM)

DYAI0.0%

NEUP0.0%

Interest Coverage (TTM)

DYAIN/A

NEUPN/A

Net Debt/EBITDA (TTM)

DYAI0.00x

NEUP0.00x

Beta

DYAI1.09

NEUP0.76

52W Performance

DYAI-60.7%

NEUP-81.7%

YTD Performance

DYAI-52.8%

NEUP-12.0%

% from 52W High

DYAI-72.2%

NEUP-82.5%

% from 52W Low

DYAI30.6%

NEUP5.3%

Asset Turnover (TTM)

DYAI0.42x

NEUP0.04x

FCF Yield (TTM)

DYAI-45.8%

NEUP-68.1%

Earnings Yield (TTM)

DYAI-47.1%

NEUP-74.1%

Dividend Yield (TTM)

DYAIN/A

NEUPN/A

Rule of 40

DYAI-202.8

NEUP-1,144.5

EV/GP/RG

DYAI0.30

NEUPN/A

Ticker research

View DYAI research View NEUP research

Metric	DYAI Dyadic International Inc	NEUP Neuphoria Therapeutics Inc
Market & Valuation
Market Cap	$16M	$18M
Enterprise Value	$20M	$-2M
Price	$0.44	$3.36
P/E Ratio	N/A	N/A
P/S Ratio	4.26x	15.45x
EV/Sales	5.21x	-1.44x
EV/EBITDA	75.44x	0.00x
P/B Ratio	14.82x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.67x	0.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.15x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$1M
Revenue Growth (YoY)	-8.1%	-92.5%
Forward Rev Growth	91.1%	0.0%
Profitability
Gross Margin (TTM)	16.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-194.5%	-779.0%
Net Margin (TTM)	-200.5%	-1145.6%
FCF Margin (TTM)	-194.7%	-1052.0%
Net Income (TTM)	$-8M	$-13M
FCF (TTM)	$-7M	$-12M
EPS (TTM)	-$0.21	-$2.49
ROE (TTM)	-35086.0%	-5591.0%
ROA (TTM)	-8477.0%	-4222.0%
ROIC (TTM)	-8444.0%	-5583.0%
Financial Health
Cash	$1M	$20M
Debt	$5M	$34K
Net Cash/Debt	$-4M	$20M
Current Ratio (TTM)	1.65x	27.85x
Quick Ratio (TTM)	1.54x	27.33x
Debt/Equity (TTM)	4.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.09	0.76
52W Performance	-60.7%	-81.7%
YTD Performance	-52.8%	-12.0%
% from 52W High	-72.2%	-82.5%
% from 52W Low	30.6%	5.3%
Efficiency & Yields
Asset Turnover (TTM)	0.42x	0.04x
FCF Yield (TTM)	-45.8%	-68.1%
Earnings Yield (TTM)	-47.1%	-74.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-202.8	-1,144.5
EV/GP/RG	0.30	N/A
Ticker research	View DYAI research	View NEUP research